Date: 2017-02-15
Type of information: Grant
Company: Signum Biosciences (USA - NJ)
Investors: National Institute of Allergy and Infectious Diseases (NIAID) (USA)
Amount: $ 3 million
Funding type: grant
Planned used: This grant will be used for the development of a novel topical non-steroidal anti-inflammatory drug candidate for atopic dermatitis (AD). Utilizing the funding provided via a preceding Phase II grant, Signum identified SIG1451 from its isoprenylcysteine library as its lead drug candidate for AD. This Phase IIB funding will be used to take SIG1451 through IND-enabling safety/toxicology studies and into the clinic, where Post-IND clinical, chemistry and formulation work will also be performed.
Others: * On February 15, 2017, Signum Biosciences announced that the National Institute of Allergy and Infectious Diseases (NIAID) awarded the company a Small Business Innovation Research (SBIR) Phase IIB grant totaling $3.0 million over 3 years for the development of a novel topical non-steroidal anti-inflammatory drug candidate for atopic dermatitis.
Therapeutic area: Dermatological diseases
